网红黑料

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.

Please see our study website at https://www.cdclinicaltrial.com

Inclusion Criteria:

1. Male and females 鈮� 18 and 鈮� 65 years of age at time of Screening

2. Weight of 鈮� 40 kg

3. Medical history and biological evidence of active bowel inflammation documented by:

   • Minimum of approximate 1 year of Crohn's disease diagnosis confirmed through Endoscopy, and;

   • Endoscopic evidence of CD diagnosis at least 3 months prior to and/or at Screening (SES-CD 鈮� 6 by central reader), and;

   • Highly sensitive C-reactive protein (hs-CRP) > 5 mg/L at Screening.

4. Active disease defined as moderate to severe active CD at Screening defined by all

Of the following:

• Evidence of mucosal inflammation, defined as SES-CD 鈮� 6 (鈮� 4 for subjects with isolated ileal disease), and;

• Average daily very soft or liquid stool frequency (SF) 鈮� 4 and/or average daily abdominal pain (AP) score 鈮� 2 (values represent the unweighted daily averages of the corresponding sub-scores from the CDAI and total scores

  • 220).

1. Subject on treatment with corticosteroids may be included if they meet the

Following:

• prednisone or equivalent dose 鈮� 20 mg/day; or

• budesonide 鈮� 9 mg/day; or

• has been on a stable dose for at least 7 days prior to TRX103 dose.

1. Advanced therapy-refractory disease defined by:

   • Failure of two or more advanced approved therapies. Prior therapies may be

Inclusive of any combination of the following:

• TNF-alpha inhibitors

• IL-12/23 inhibitors

• Anti-integrins

• JAK inhibitors

• OR

• Non-response (primary failure), complete loss of response (secondary failure) or intolerant to therapy at a dose indicated for CD.

1. Absence of uncontrolled bacterial, viral, or fungal infection at time of enrollment.

2. Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.

Exclusion Criteria:

1. Prior organ transplant, or allogeneic bone marrow, peripheral blood, or cord blood stem cell transplant.

2. Received another investigational agent or therapy, within 28 days of planned TRX103 infusion (or 5 half-lives, whichever is longer) and/or have not recovered from treatment related toxicities.

3. Received any approved treatment for CD within the designated washout period (including off-label use of approved therapies) as per the protocol (see Table 4).

4. Strictures, active fistulae (including perianal), or abscess by computed tomography (CT) or magnetic resonance enterography (MRE) or Endoscopy within 6 months of Screening.

5. Positive serology for HIV.

6. Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.

7. Hepatitis C virus (HCV RNA detectable in any subject with anti-HCV antibodies).

8. Subject with active or chronic recurring infections or untreated latent Tuberculosis (TB).

9. Current diagnosis of ulcerative colitis (UC), indeterminate colitis or CD isolated to colon only (the colitis must be related to CD and inclusive of ileal with or without colonic involvement).

10. Subjects with the following known complications of Crohn's Disease

• active diverticulitis,

• active fistulae or abscess,

• abscess (abdominal or perianal),

• impassable fibrotic strictures,

• symptomatic bowel strictures,

• fulminant colitis,

• toxic megacolon,

• ostomy or ileoanal pouch,

• diagnosed with short gut or short bowel syndrome,

• or any other manifestation that might require surgery while enrolled in the study.

1. Subject with surgical bowel resection within the past 3 months prior to Screening,

or a history of > 2 bowel resections.

1. Subjects that are pregnant, breast feeding, or aim to become pregnant during the 12

month study period. (Subjects, males and females, must agree to use a highly

effective method of contraception).

1. Screening laboratory and other analyses show any of the following abnormal results:

• Serum aspartate transaminase or alanine transaminase > 3.0 脳 upper limit of normal;

• Total white blood cell count < 2,000/渭L;

• Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula < 40 mL/min/1.73 m2;

• Hemoglobin < 8 g/dL;

• Bilirubin 鈮� 2 x ULN;

• Platelet count < 100,000/渭L;

• Absolute neutrophil count < 1,200/渭L;

• Absolute lymphocytes count < 750/渭L.

1. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac

dysfunction, or on treatment to support cardiac dysfunction.

1. Any serious illness, uncontrolled inter-current illness, psychiatric illness, active

or uncontrolled infection, or other medical condition or history, including

laboratory results, which, in the Investigator's opinion:

• places the subject at increased risk during participation in the study, and/or;

• interferes with the subject's capacity to provide informed consent and their participation in the study, and/or;

• interferes with the interpretation of the results.